Treatment of levodopa-induced motor complications
- PMID: 18781681
- DOI: 10.1002/mds.22052
Treatment of levodopa-induced motor complications
Abstract
Chronic levodopa treatment for Parkinson's disease patients is frequently associated with the development of motor complications such as end-of-dose wearing-off and dyskinesias. In this review, we provide an overview of the strategies available for dealing with these problems. Medical management includes manipulation of levodopa dosing to establish the optimum treatment schedule, improving levodopa absorption, catechol-O-methyl transferase-inhibition (COMT), Monoamine oxidase-B (MAO-B) inhibition, dopaminergic agonists, amantadine, and continuous dopaminergic infusions. Surgical procedures and particularly deep brain stimulation are also reviewed. It should be noted that none of these treatments has been shown to provide anti-parkinsonian efficacy that is greater than what can be achieved with levodopa. We highlight the importance of initiating therapy with a treatment strategy that reduces the risk that a Parkinson's disease patient will develop motor complications in the first place. Key Words: Advanced PD, dyskinesias, motor fluctuations, levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors.
(c) 2008 Movement Disorder Society.
Similar articles
-
Other pharmacological treatments for motor complications and dyskinesias.Mov Disord. 2005;20 Suppl 11:S38-44. doi: 10.1002/mds.20462. Mov Disord. 2005. PMID: 15822104 Review.
-
Pharmacotherapy for Parkinson's disease.Pharmacotherapy. 2007 Dec;27(12 Pt 2):161S-173S. doi: 10.1592/phco.27.12part2.161S. Pharmacotherapy. 2007. PMID: 18041936 Review.
-
Mid-stage parkinsonism with mild motor fluctuations.Clin Neuropharmacol. 1994;17 Suppl 2:S19-31. Clin Neuropharmacol. 1994. PMID: 9358192 Review.
-
Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.J Med Assoc Thai. 2009 Jan;92(1):142-54. J Med Assoc Thai. 2009. PMID: 19260256 Review.
-
Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.J Am Med Dir Assoc. 2006 Sep;7(7 Suppl 2):4-10. J Am Med Dir Assoc. 2006. PMID: 17948613 Review.
Cited by
-
Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.Mov Disord. 2017 Nov;32(11):1547-1556. doi: 10.1002/mds.27077. Epub 2017 Jun 20. Mov Disord. 2017. PMID: 28631864 Free PMC article.
-
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21824-9. doi: 10.1073/pnas.1012071107. Epub 2010 Nov 29. Proc Natl Acad Sci U S A. 2010. PMID: 21115823 Free PMC article.
-
Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.Funct Neurol. 2012 Jul-Sep;27(3):147-54. Funct Neurol. 2012. PMID: 23402675 Free PMC article. Review.
-
mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.Curr Neuropharmacol. 2016;14(5):481-93. doi: 10.2174/1570159x14666151201185652. Curr Neuropharmacol. 2016. PMID: 26639458 Free PMC article. Review.
-
Clinical aspects and management of levodopa-induced dyskinesia.Parkinsons Dis. 2012;2012:745947. doi: 10.1155/2012/745947. Epub 2012 Jun 3. Parkinsons Dis. 2012. PMID: 22701811 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous